中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2010年
5期
320-323
,共4页
张卫红%田钢龙%何继民%周凤飞%关宏霞%高聪明%吕平欣
張衛紅%田鋼龍%何繼民%週鳳飛%關宏霞%高聰明%呂平訢
장위홍%전강룡%하계민%주봉비%관굉하%고총명%려평흔
乳腺肿瘤%肿瘤转移%骨骼%放射性核素显像%MDP
乳腺腫瘤%腫瘤轉移%骨骼%放射性覈素顯像%MDP
유선종류%종류전이%골격%방사성핵소현상%MDP
Breast neoplasms%Neoplasm metastasis%Skeleton%Radionuclide imaging%MDP
目的 研究乳腺癌骨转移的临床和影像学资料,寻找影响骨转移的相关因素,为早期诊断提供依据.方法 对334例乳腺癌患者全身骨显像、临床分期、病理、免疫组织化学及血清学检-查结果进行回顾性分析,并对数据行χ2检验.结果 有淋巴结转移者骨转移率71.0%(152/214),没有淋巴结转移者骨转移率为22.5%(27/120),两者比较差异有统计学意义(χ2=72.80,P=0.000);浸润性非特殊性癌骨转移率69.0%(203/294),浸润性特殊性癌骨转移率41.7%(5/12),两者比较差异有统计学意义(χ2=3.97,P=0.046);骨转移中碱性磷酸酶(ALP)升高者占28.5%(51/179),非骨转移中ALP升高者占14.9%(11/74),两者比较差异也有统计学意义(χ2=5.25,P=0.022);而骨转移中肿瘤标志物[癌胚抗原(CEA)、糖类抗原(CA)15-3、CA125、CA19-9]升高者占68.7%(123/179),非骨转移中肿瘤标志物升高者占27.0%(20/74)(χ2=37.03,P=0.000).结论 乳腺癌骨转移的发生率与原发灶的病理类型、发病时有无淋巴结转移有关,浸润性非特殊性癌或有淋巴结转移者骨转移率较高.动态监测血清ALP、CEA、CA15-3、CA125、CA19-9有助于早期诊断.
目的 研究乳腺癌骨轉移的臨床和影像學資料,尋找影響骨轉移的相關因素,為早期診斷提供依據.方法 對334例乳腺癌患者全身骨顯像、臨床分期、病理、免疫組織化學及血清學檢-查結果進行迴顧性分析,併對數據行χ2檢驗.結果 有淋巴結轉移者骨轉移率71.0%(152/214),沒有淋巴結轉移者骨轉移率為22.5%(27/120),兩者比較差異有統計學意義(χ2=72.80,P=0.000);浸潤性非特殊性癌骨轉移率69.0%(203/294),浸潤性特殊性癌骨轉移率41.7%(5/12),兩者比較差異有統計學意義(χ2=3.97,P=0.046);骨轉移中堿性燐痠酶(ALP)升高者佔28.5%(51/179),非骨轉移中ALP升高者佔14.9%(11/74),兩者比較差異也有統計學意義(χ2=5.25,P=0.022);而骨轉移中腫瘤標誌物[癌胚抗原(CEA)、糖類抗原(CA)15-3、CA125、CA19-9]升高者佔68.7%(123/179),非骨轉移中腫瘤標誌物升高者佔27.0%(20/74)(χ2=37.03,P=0.000).結論 乳腺癌骨轉移的髮生率與原髮竈的病理類型、髮病時有無淋巴結轉移有關,浸潤性非特殊性癌或有淋巴結轉移者骨轉移率較高.動態鑑測血清ALP、CEA、CA15-3、CA125、CA19-9有助于早期診斷.
목적 연구유선암골전이적림상화영상학자료,심조영향골전이적상관인소,위조기진단제공의거.방법 대334례유선암환자전신골현상、림상분기、병리、면역조직화학급혈청학검-사결과진행회고성분석,병대수거행χ2검험.결과 유림파결전이자골전이솔71.0%(152/214),몰유림파결전이자골전이솔위22.5%(27/120),량자비교차이유통계학의의(χ2=72.80,P=0.000);침윤성비특수성암골전이솔69.0%(203/294),침윤성특수성암골전이솔41.7%(5/12),량자비교차이유통계학의의(χ2=3.97,P=0.046);골전이중감성린산매(ALP)승고자점28.5%(51/179),비골전이중ALP승고자점14.9%(11/74),량자비교차이야유통계학의의(χ2=5.25,P=0.022);이골전이중종류표지물[암배항원(CEA)、당류항원(CA)15-3、CA125、CA19-9]승고자점68.7%(123/179),비골전이중종류표지물승고자점27.0%(20/74)(χ2=37.03,P=0.000).결론 유선암골전이적발생솔여원발조적병리류형、발병시유무림파결전이유관,침윤성비특수성암혹유림파결전이자골전이솔교고.동태감측혈청ALP、CEA、CA15-3、CA125、CA19-9유조우조기진단.
Objective To study the clinical and imaging features of patients with bone metastases from breast cancer and identify the factors related to the incidence of bone metastases. Methods Three hundred and thirty-four patients with breast cancer were recruited into this study. Whole-body 99Tcm-methylene disphosphonate (MDP) bone scan, clinical staging, pathological, immunohistochemical and serological test results were analyzed retrospectively. χ2 test was used for statistical analysis. Results The incidence rate of bone metastases for patients with and without lymph node metastases was 71% (152/214) and 22. 5% (27/120), respectively (χ2 =72.80, P =0.000). The incidence rate of bone metastases from infiltrated non-specified and specified breast cancer was 69% (203/294) and 41.7% (5/12), respectively (χ2 =3. 97, P=0.046). Alkaline phosphatase (ALP) was elevated in 28.5% (51/179) and 14.9%(11/74) of patients with and without bone metastases, respectively (χ2 = 5. 25, P = 0.022 ). Carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 15-3, CA125, CA19-9 increased in 68.7% ( 123/179) and 27.0% (20/74) of patients with and without bone metastases, respectively (χ2 = 37. 03, P =0. 000). Conclusions The incidence of bone metastases from breast cancer is correlated to pathological types of primary tumor and lymph node metastases. Bone metastases occurs more frequently in patients with infiltrated, non-specified, primary cancer and with lymph node metastases. Serum ALP, CEA, CA15-3,CA125, CA19-9 might be the tumor makers for early diagnosis of bone metastases from breast cancer.
